Compare BRZE & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRZE | RNA |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 4.0B |
| IPO Year | 2021 | 2020 |
| Metric | BRZE | RNA |
|---|---|---|
| Price | $30.31 | $71.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 20 |
| Target Price | $44.53 | ★ $69.26 |
| AVG Volume (30 Days) | 1.2M | ★ 2.9M |
| Earning Date | 12-09-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $654,622,000.00 | $20,868,000.00 |
| Revenue This Year | $23.36 | $64.11 |
| Revenue Next Year | $17.31 | $37.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 22.16 | ★ 106.27 |
| 52 Week Low | $23.91 | $21.51 |
| 52 Week High | $48.33 | $71.79 |
| Indicator | BRZE | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 64.17 | 77.56 |
| Support Level | $27.76 | $71.42 |
| Resistance Level | $29.56 | $71.76 |
| Average True Range (ATR) | 1.07 | 0.41 |
| MACD | 0.28 | -0.73 |
| Stochastic Oscillator | 80.41 | 88.32 |
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates majority of its revenue from the United States.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.